46662-2020 - Tiešas piešķiršanas priekšpaziņojums

See the notice on TED website

Apvienotā Karaliste-Bristole: Patoloģijas pakalpojumi
OJ S 21/2020 30/01/2020
Brīvprātīgas ex-ante pārskatāmības paziņojums
Pakalpojumi

Juridiskais pamats:
Direktīva 2014/24/ES

I iedaļa: Līgumslēdzēja iestāde/līgumslēdzējs

I.1. Nosaukums un adreses

Pilns nosaukums: North Bristol NHS Trust
Pasta adrese: Southmead Road, Bristol
Pilsēta: Bristol
NUTS kods: UKK11 Bristol, City of
Pasta indekss: BS10 5NB
Valsts: Apvienotā Karaliste
Kontaktpersona: Martin Strawson
E-pasts: martin.strawson@UHBristol.nhs.uk
Tālrunis: +44 1173420815
Interneta adrese(-es):
Galvenā adrese: https://www.nbt.nhs.uk/

I.4. Līgumslēdzējas iestādes veids

Cits veids: NHS trust

I.5. Galvenā darbības joma

Veselība

II iedaļa: Priekšmets

II.1. Iepirkuma apjoms

II.1.1. Nosaukums

Procurement of a Large Throughput DNA Sequencer
Atsauces numurs: BWPCCL001501

II.1.2. Galvenās CPV kods

85111800 Patoloģijas pakalpojumi

II.1.3. Līguma veids

Pakalpojumi

II.1.4. Īss apraksts

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Informācija par daļām
Līgums ir sadalīts daļās: nē

II.1.7. Iepirkuma kopējā vērtība
Vērtība bez PVN: 779 625,00 GBP

II.2. Apraksts

II.2.2. Papildu CPV kods(-i)
85111000 Slimnīcu pakalpojumi

II.2.3. Izpildes vieta
NUTS kods: UKK11 Bristol, City of

II.2.4. Iepirkuma apraksts
North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a ‘universal’ gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Līguma slēgšanas tiesību piešķiršanas kritēriji
Kvalitātes kritērijs - Nosaukums: Quality / Svērums: 90
Cena - Svērums: 10

II.2.11.

Informācija par iespējām
Iespējas: nē

II.2.13. Informācija par Eiropas Savienības fondiem
Iepirkums ir saistīts ar projektu un/vai programmu, ko finansē no Eiropas Savienības fondiem: nē

II.2.14. Papildu informācija

IV iedaļa: Procedūra

IV.1. Apraksts

IV.1.1. Procedūras veids
Līguma slēgšanas tiesību piešķiršana, neizsludinot iepirkumu ar iepriekšēju publikāciju Eiropas Savienības Oficiālajā Vēstnesī, gadījumos, kas uzskaitīti turpmāk

- Iepirkums neietilpst attiecīgās direktīvas darbības jomā

Paskaidrojums:
North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a ‘universal’ gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Informācija par pamatnolīgumu

IV.1.8. Informācija par Valsts iepirkuma nolīgumu (GPA)
Uz iepirkumu attiecas Valsts iepirkuma nolīgums: nē

IV.2. Administratīvā informācija

V iedaļa: Līguma/koncesijas piešķiršana

Nosaukums:
Procurement of Large High Throughput DNA Sequencer

V.2. Līguma/koncesijas piešķiršana

V.2.1. Līguma slēgšanas tiesību piešķiršanas lēmuma datums
28/01/2020

V.2.2. Informācija par piedāvājumiem
Līgums ir piešķirts ekonomikas dalībnieku grupai: nē

V.2.3. Darbuzņēmēja/koncesionāra nosaukums un adrese
Pilns nosaukums: Illumina Cambridge Ltd
Pasta adrese: Chesterford Research Park, Little Chesterford
Pilsēta: Saffron Walden
NUTS kods: UKI London
Pasta indekss: CB10 1XL
Valsts: Apvienotā Karaliste
Darbuzņēmējs/koncesionārs būs MVU: jā

V.2.4. Informācija par līguma/daļas/koncesijas vērtību
Līguma/daļas/koncesijas kopējā vērtība: 779 625,00 GBP

V.2.5. Informācija par apakšuzņēmuma līgumiem

VI iedaļa: Papildinformācija

VI.3. Papildu informācija

VI.4. Pārskatīšanas procedūras

VI.4.1. Struktūra, kas atbildīga par pārskatīšanu
Pilns nosaukums: Bristol and Weston Purchasing Consortium
Pasta adrese: Level 3, Whitefriars, Lewins Mead
Pilsēta: Bristol
Pasta indekss: BS1 2NT
Valsts: Apvienotā Karaliste
E-pasts: martin.strawson@UHBristol.nhs.uk

VI.4.2. Struktūra, kas atbildīga par pārskatīšanas procedūrām
Pilns nosaukums: Bristol and Weston Purchasing Consortium
Pasta adrese: Level 3, Whitefriars, Lewins Mead
Pilsēta: Bristol
Pasta indekss: BS1 2NT
Valsts: Apvienotā Karaliste

VI.4.4. Dienests, no kura var iegūt informāciju par pārskatīšanas procedūru
Pilns nosaukums: Bristol and Weston Purchasing Consortium
Pasta adrese: Level 3, Whitefriars, Lewins Mead

Pilsēta: Bristol
Pasta indekss: BS1 2NT
Valsts: Apvienotā Karaliste

VI.5. Šā paziņojuma nosūtīšanas datums
28/01/2020